- Home
- NRXP vs CGTX Comparison
NRXP vs CGTX Comparison
Compare NRXP & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRXP | CGTX |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.5M | 158.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NRXP | CGTX |
|---|---|---|
| Price | $2.11 | $1.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $30.50 | $2.88 |
| AVG Volume (30 Days) | 461.9K | ★ 942.9K |
| Earning Date | 11-17-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $242,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $643.59 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.17 | $0.22 |
| 52 Week High | $6.01 | $3.83 |
Technical Indicators
Market Signals| Indicator | NRXP | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.68 | 45.55 |
| Support Level | $2.22 | $1.69 |
| Resistance Level | $2.24 | $1.76 |
| Average True Range (ATR) | 0.16 | 0.12 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 26.32 | 22.94 |
Price Performance
Historical ComparisonAbout NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.